BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation to Advance Digital Health Innovation through AI adoption in Healthcare FOR IMMEDIATE RELEASE .
KUALA LUMPUR, Malaysia, April 19, 2024 BioNexus Gene Lab Corporation , a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned.
Routinely screening adults age 40 and younger for three genetic conditions that carry a high risk of serious illness is cost-effective based on quality and quantity of life measures, a new study shows.
Early surgery may benefit patients shown to be at risk for medullary thyroid cancer through genetic screening program, but overall merit of such gene testing remains debatable, say editorialists.